Drug Type Small molecule drug |
Synonyms LNS 8801 |
Target |
Action agonists |
Mechanism GPER1 agonists(G protein-coupled estrogen receptor 1 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2/3 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Molecular FormulaC21H18BrNO3 |
InChIKeyVHSVKVWHYFBIFJ-HKZYLEAXSA-N |
CAS Registry- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Melanoma, Cutaneous Malignant | Phase 3 | United States | 06 Aug 2025 | |
Unresectable Melanoma | Phase 3 | United States | 06 Aug 2025 | |
Advanced cancer | Phase 2 | United States | 21 Oct 2019 | |
Advanced Malignant Solid Neoplasm | Phase 2 | United States | 21 Oct 2019 | |
Colorectal Cancer | Phase 2 | United States | 21 Oct 2019 | |
Lymphoma | Phase 2 | United States | 21 Oct 2019 | |
metastatic non-small cell lung cancer | Phase 2 | United States | 21 Oct 2019 | |
Uveal Melanoma | Phase 2 | United States | 21 Oct 2019 | |
Pancreatic Cancer | Preclinical | United States | 08 Sep 2019 |
Phase 1 | Melanoma germline GPER | 9 | jpzgkaqmwb(awzxcpsxxc) = G3 and G1 leafpcpvaj (zrsyckyixc ) View more | Positive | 14 Sep 2024 | ||
Phase 1/2 | Refractory Melanoma consensus germline GPER | 10 | qbbsyooddc(jwscsopdam) = zmkvxziwva wvqcibdxzu (utodmmrjff ) View more | Positive | 02 Nov 2023 | ||
Phase 1/2 | - | wrpwpfxqtx(aqnsymvtug) = cmjwtmslsh rmyuwgqzku (azjoynqomr ) View more | - | 22 Oct 2023 | |||
NCT04130516 (ASCO2023) Manual | Phase 1/2 | 15 | uydgdgvpvb(axkiybzvcn) = 4 of 8 monotherapy patients had AEs potentially related to study drug (all grade 1), with no AEs occurring in more than one patient. 6 of 7 combination patients had AEs potentially related to study drugs (grades 1-2), with fatigue occurring in more than one patient. ridnswjgkm (ozpawerlzl ) | Positive | 31 May 2023 | ||
Phase 1/2 | 13 | leruoubpth(aobgnryxma) = LNS8801 was identified as 125 mg daily as a monotherapy and in combination with pembrolizumab (200 mg every 3 weeks) gahnuokfjv (isotzzjvqz ) | Positive | 06 Jun 2022 | |||
NCT04130516 (ASCO2022) Manual | Phase 1 | 13 | ulktzcacam(mhdzxskocn) = mewsjfnkgf eljukdwuku (szxuotukec ) View more | Positive | 02 Jun 2022 | ||
Phase 1 | 33 | gkuixzpkxz(hiltpzlhoa) = edjawflidj uhsznilsil (rzwpixpfwt ) View more | Positive | 20 May 2021 | |||
gkuixzpkxz(hiltpzlhoa) = evifkirgwe uhsznilsil (rzwpixpfwt ) View more |